ArticlemBio2021
IS
Article in mBio, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 20 citations in OpenAlex.
- ISmLife · 2026Article
- Heterogeneous multicopy of blaNature communications · 2026Article
- Novel KPC-2 variants and epidemic ST463 clones underlie ceftazidime/avibactam resistance in carbapenem-resistantMicrobiology spectrum · 2026Article
- Comparative analysis of virulence and resistance gene profiles between carbapenem-resistant and ESBL-producingFrontiers in microbiology · 2026Article
- Article
- Transfer and Fitness of ISMicroorganisms · 2025Article
- Emergence of carbapenem-resistantMicrobiology spectrum · 2025Article
- Driving factors for beta-lactam resistance gene amplification duringAntimicrobial agents and chemotherapy · 2025Article
- Oral and parenteral treatment with a third-generation cephalosporin promotes the proliferation of diverse ESBL-producingmSphere · 2025Article
- Insertion sequences accelerate genomic convergence of multidrug resistance and hypervirulence in Klebsiella pneumoniae via capsular phase variation.Genome medicine · 2025Article
- Progression ofmBio · 2025Article
- Co-Production of KPC-2 and NDM-5 in a Carbapenem-ResistantInfection and drug resistance · 2025Article
- Drivers of antimicrobial resistance in pig production systems of Uganda.Communications earth & environment · 2025Article
- Article
- The Difference a Year Can Make: How Antibiotic Resistance Mechanisms inBiomolecules · 2024Article
- Decadal Evolution of KPC-related plasmids in Pseudomonas aeruginosa high-risk clone ST463 in Zhejiang, China.Communications biology · 2024Article
- Prevalence and characteristics of ertapenem-mono-resistant isolates among carbapenem-resistant Enterobacterales in China.Emerging microbes & infections · 2024Article
- ISMicrobiology and molecular biology reviews : MMBR · 2024Review
- Generation and maintenance of the circularized multimeric IS26-associated translocatable unit encoding multidrug resistance.Communications biology · 2024Article
- Article
Corrections and comments
- Erratum issued
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multidrug-resistant Gram-negative carriers of Klebsiella pneumoniae carbapenemases (KPCs) often subvert antibiotic therapy due to inadequate sensitivity in laboratory detection. Although unstable gene amplification has been recognized to crucially contribute to underestimation or misestimation of antimicrobial resistance in clinical isolates, the precise mechanisms underlying carbapenem resistance driven by amplification of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.